

ASX Announcement

29 October 2024

OncoSil Medical Appoints Rachel Duggan as EMEA Sales Director

Sydney, Australia – 29 October 2024: Pancreatic cancer treatment device company **OncoSil Medical Limited (ASX:OSL)** (“OncoSil” or “the Company”) is pleased to announce that Rachel Duggan will join the company as EMEA Sales Director, effective from 29th October 2024.

Rachel returns to OncoSil after a brief period pursuing other opportunities, having previously served as Regional Lead for the UK and Ireland. With over 15 years of experience in the medical device and pharmaceutical industries, including more than a decade dedicated to oncology, Rachel brings a wealth of expertise to this role. Throughout her career, she has been instrumental in introducing new and innovative treatments to market, developing strategic pathways, and building strong sales teams.

During her seven years at BTG, Rachel successfully introduced SIRT and Cryotherapy to the UK market and played a key role in developing the UK sales force. She has also held various leadership positions in sales and marketing at BTG, Boston Scientific, and SERB Pharmaceuticals.

Rachel’s passion for getting life-changing treatments to patients, along with her deep expertise in the oncology space, makes her a valuable addition to OncoSil as we continue to expand our reach and provide innovative solutions to patients across Europe, the Middle East, and Africa.

Rachel expressed her enthusiasm about rejoining OncoSil in this new capacity:

“I am thrilled to return to OncoSil Medical and take on this role as EMEA Sales Director. OncoSil’s commitment to bringing life-changing treatments to patients aligns with my passion for advancing healthcare. I look forward to working alongside our talented team to expand our impact in the EMEA region and to continue delivering innovative solutions that make a real difference for patients.”

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

“We are delighted to welcome Rachel back to the team. Her extensive experience in launching breakthrough therapies and her deep understanding of the oncology market will be invaluable as we continue to grow OncoSil’s presence in the EMEA region. We look forward to her leadership in advancing our mission to bring innovative cancer treatments to patients in need.”

Authorisation & Additional Information

This announcement was authorised by the Chairman of OncoSil Medical Limited.

For further information, please contact:

Mr. Nigel Lange CEO & Managing Director E: nigel.lange@oncosil.com T: +49 30 300 149 3043	Mr. Christian Dal Cin CFO & Company Secretary E: c.dalcin@acclime.com T: +61 3 9824 5254	Ms. Julia Maguire The Capital Network Media and Investor Enquiries E: julia@thecapitalnetwork.com.au T: +61 2 8999 3699
--	--	---

About OncoSil Medical

OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for long-term survival¹.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (³²P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient's pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy.

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com/

References: 1. <https://www.wcrf.org/cancer-trends/pancreatic-cancer-statistics/>